Novo Nordisk's Wegovy clinical data beats Eli Lilly, leading the European stock medical sector
I'm PortAI, I can summarize articles.
Novo Nordisk's weight loss drug Wegovy outperformed Eli Lilly's similar products in terms of heart protection effects, driving its stock price up nearly 3%. On Monday, European stock markets rose slightly, with the pan-European Stoxx 600 index increasing by 0.29%. The healthcare sector became a major supporting force, performing the best. Meanwhile, the defense sector also showed strong performance, with BAE Systems' stock price rising by 2%
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments